TY - JOUR
T1 - Development of a novel apixaban-loaded solid self-emulsifying drug delivery system for oral administration
T2 - physicochemical characterization and pharmacokinetics in rats
AU - Lee, Hye In
AU - Woo, Mi Ran
AU - Din, Fakhar ud
AU - Kim, Jung Suk
AU - Cheon, Seunghyun
AU - Park, Seonghyeon
AU - Woo, Sanghyun
AU - Jin, Sung Giu
AU - Choi, Han Gon
N1 - Publisher Copyright:
© The Author(s) under exclusive licence to The Korean Society of Pharmaceutical Sciences and Technology 2024.
PY - 2025/7
Y1 - 2025/7
N2 - Purpose: The aim of this study was to develop a novel apixaban-loaded solid self-emulsifying drug delivery system (S-SEDDS) to enhance oral bioavailability. Methods: Oils, surfactants, and co-surfactants were screened based on the solubility of apixaban to select the most suitable for the preparation of apixaban-loaded liquid SEDDS. Next, 1 mL of the liquid SEDDS was suspended in distilled water (100 mL) and spray-dried with 0.75 g of Aerosil 200 (a mesoporous carrier) using a fluid bed granulator to produce apixaban-loaded S-SEDDS. First, the concentration of Aerosil 200 was optimized. Physiochemical properties were investigated using scanning electron microscopy (SEM), differential scanning calorimetry (DSC), and powder X-ray diffraction (PXRD) to examine the morphology, thermal behavior, and crystallinity of the S-SEDDS, respectively. Additionally, the in vitro dissolution and in vivo bioavailability of the S-SEDDS were investigated and compared with those of the powdered drug. Results: The liquid SEDDS consisting of Peceol/Labrasol/Cremophor EL at a volume ratio of 15/35/50 presented the smallest emulsion droplet size among all the prepared formulations. The optimized S-SEDDS2 showed maximum drug solubility. Moreover, the physicochemical findings suggested that the S-SEDDS had a rounded morphology and thermal stability, and that crystalline apixaban was converted to an amorphous form. This formulation showed significant improvements in drug solubility (4-fold), dissolution (5.6-fold), and bioavailability (3.2-fold) compared with apixaban powder. Conclusion: S-SEDDSs may be efficiently used to improve the solubility, dissolution, and oral bioavailability of poorly water-soluble drugs, as demonstrated by the apixaban-loaded S-SEDDS.
AB - Purpose: The aim of this study was to develop a novel apixaban-loaded solid self-emulsifying drug delivery system (S-SEDDS) to enhance oral bioavailability. Methods: Oils, surfactants, and co-surfactants were screened based on the solubility of apixaban to select the most suitable for the preparation of apixaban-loaded liquid SEDDS. Next, 1 mL of the liquid SEDDS was suspended in distilled water (100 mL) and spray-dried with 0.75 g of Aerosil 200 (a mesoporous carrier) using a fluid bed granulator to produce apixaban-loaded S-SEDDS. First, the concentration of Aerosil 200 was optimized. Physiochemical properties were investigated using scanning electron microscopy (SEM), differential scanning calorimetry (DSC), and powder X-ray diffraction (PXRD) to examine the morphology, thermal behavior, and crystallinity of the S-SEDDS, respectively. Additionally, the in vitro dissolution and in vivo bioavailability of the S-SEDDS were investigated and compared with those of the powdered drug. Results: The liquid SEDDS consisting of Peceol/Labrasol/Cremophor EL at a volume ratio of 15/35/50 presented the smallest emulsion droplet size among all the prepared formulations. The optimized S-SEDDS2 showed maximum drug solubility. Moreover, the physicochemical findings suggested that the S-SEDDS had a rounded morphology and thermal stability, and that crystalline apixaban was converted to an amorphous form. This formulation showed significant improvements in drug solubility (4-fold), dissolution (5.6-fold), and bioavailability (3.2-fold) compared with apixaban powder. Conclusion: S-SEDDSs may be efficiently used to improve the solubility, dissolution, and oral bioavailability of poorly water-soluble drugs, as demonstrated by the apixaban-loaded S-SEDDS.
KW - Apixaban
KW - Dissolution
KW - Oral bioavailability
KW - Self-emulsifying drug delivery system
UR - https://www.scopus.com/pages/publications/85207917239
U2 - 10.1007/s40005-024-00709-3
DO - 10.1007/s40005-024-00709-3
M3 - Article
AN - SCOPUS:85207917239
SN - 2093-5552
VL - 55
SP - 575
EP - 588
JO - Journal of Pharmaceutical Investigation
JF - Journal of Pharmaceutical Investigation
IS - 4
ER -